Efficacy of different antibiotics in treatment of children with respiratory mycoplasma infection

ARTICLE HIGHLIGHTS

Research background

Children are more susceptible to infection with Mycoplasma pneumoniae. At the same time, they are more susceptible to disease after infection and have difficulty breathing and can experience respiratory failure or critical illness. The treatment of this disease has received widespread clinical attention.

Research motivation

To search drugs that can replace erythromycin in the treatment of respiratory tract infections in children.

Research objectives

This study aimed to analyze the clinical efficacy of different antibiotics in the treatment of pediatric respiratory mycoplasma infection.

Research methods

One hundred and six children diagnosed with respiratory mycoplasma infection were included in this study. The clinical efficacy was evaluated and compared between groups. The compliance of children during treatment was evaluated and compared between groups.

Research results

The total effective rate of clinical treatment of children in the clarithromycin group was significantly higher than that in the erythromycin group. The incidence of toxic and side effects in the clarithromycin group was significantly lower than that in the erythromycin group, and the above data comparisons were statistically significant.

Research conclusions

Clarithromycin has a variety of advantages over erythromycin, such as higher application safety, stronger mycoplasma clearance, and higher medication compliance in children, and can be actively promoted.

Research perspectives

Clarithromycin is superior to erythromycin in terms of application effect, safety, and economic benefits and can be preferentially selected.